Modulating ALS-Related Amyloidogenic TDP-43_307-319 Oligomeric Aggregates with Computationally Derived Therapeutic...

Area of Science:

• Neuroscience
• Biochemistry
• Drug Discovery

Background:

• TDP-43 aggregates are key pathological hallmarks in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD).
• Neurodegenerative diseases are projected to affect 15 million people in the US by 2050, with no current cures available.
• Toxicity is linked to TDP-43 oligomers larger than trimers, highlighting a therapeutic target.

Purpose of the Study:

• To design and evaluate novel drug candidates targeting toxic TDP-43 oligomers.
• To assess the efficacy of joint pharmacophore space (JPS) generated molecules in disrupting oligomer formation.
• To compare the effects of JPS inhibitors with FDA-approved ALS drugs on TDP-43 oligomers.

Main Methods:

• Utilized the joint pharmacophore space (JPS) computational method to design potential drug molecules.
• Employed ion-mobility mass spectrometry and atomic force microscopy to evaluate drug efficacy.
• Assessed the impact of novel inhibitors on TDP-43 oligomer size and stability.

Main Results:

• JPS-generated inhibitors effectively dissociated higher-order TDP-43 oligomers into smaller species.
• FDA-approved ALS drugs did not disrupt TDP-43 oligomer formation, maintaining higher-order assemblies.
• Demonstrated the potential of JPS inhibitors to interfere with the development of toxic TDP-43 species.

Conclusions:

• Novel JPS-designed molecules show potential for treating TDP-43 proteinopathies.
• These inhibitors offer a promising therapeutic strategy by disrupting toxic oligomer formation.
• Further research into the mechanisms of JPS molecules is warranted for neurodegenerative disease treatment.